22.03.2024 • News

Afyren Neoxy Gets €3.4 Million in After-Biochem Project

Greentech firm Afyren Neoxy, a subsidiary of Afyren, received a €3.4 million payment this week for achieving key milestones with its bio-based low-carbon products.

Afyren Neoxy’s €20 million grant from the Circular Bio-based Europe Joint Undertaking (CBE JU) saw its third installment recognized in the 2023 accounts. The After-Biochem project, led by a consortium of 12 partners including Afyren Neoxy, aims to create sustainable value chains from renewable, non-food raw materials. The project, which also focuses on downstream markets, received the third grant installment after meeting a set of achievements.

The After-Biochem project, backed by CBE JU, will persist with an emphasis on plant performance during the production phase. This includes life cycle and product performance analysis with end-user partners. Future developments, such as plant replication and new product projects, will also be evaluated.

With the recent payment, CBE JU’s total support for After-Biochem has reached €16 million in the last four years. 90% of this was directly invested in Afyren Neoxy, aiding all development phases of the plant. The factory’s initial total CAPEX is around €62 million. The French state investment bank BPI holds a 49% stake in Afyren Neoxy.

Afyren Neoxy receives €3.4 million milestone payment as part of the...
Afyren Neoxy receives €3.4 million milestone payment as part of the After-Biochem project. © Afyren Neoxy

Company

Logo:

AFYREN SAS

9-11 rue Gutenberg
63100 Clermont-Ferrand
France

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read